Table 1.
Patients undergoing the procedure – clinical characteristics.
| Clinical data | Group I | Group II | P-value |
|---|---|---|---|
| (n = 505) | (n = 597) | ||
| # (%) | # (%) | ||
| Mean age (years) and range | 58.7 (25–85) | 59.4 (27–87) | 0.2421 |
| BMI (mean) | 27.08 ± 4.98 | 27.43 ± 5.08 | 0.2484 |
| Histological type | |||
| invasive ductal | 446 (88.3%) | 513 (85.9%) | 0.2379 |
| invasive lobular | 42 (8.3%) | 64 (10.7%) | 0.1778 |
| invasive – other types | 17 (3.4%) | 20 (3.4%) | 0.9883 |
| Presence of DCIS | 164 (32.5%) | 221 (37.0%) | 0.1185 |
| Presence of comedo necrosis | 11 (2.2%) | 13 (2.2%) | 0.9994 |
| Tumor multifocality | 81 (16.0%) | 113 (18.9%) | 0.2075 |
| Tumor stage | |||
| T1 | 310 (61.4%) | 395 (66.2%) | 0.0981 |
| T2 | 191 (37.8%) | 190 (31.8%) | 0.0369 |
| T3 | 4 (0.8%) | 12 (2.0%) | 0.0968 |
| Palpable tumor mass | 357 (70.7%) | 370 (62.0%) | 0.0024 |
| Histological grade | |||
| G1 | 25 (5.0%) | 27 (4.5%) | 0.6968 |
| G2 | 352 (69.7%) | 445 (74.5%) | 0.076 |
| G3 | 107 (21.2%) | 100 (16.8%) | 0.0626 |
| nd | 21 (4.2%) | 25 (4.2%) | 0.9809 |
| ER positive | 428 (84.8%) | 498 (83.4%) | 0.5272 |
| PR positive | 385 (76.2%) | 433 (72.5%) | 0.1619 |
| HER2 positive | 62 (12.3%) | 73 (12.2%) | 0.9598 |
| Molecular subtype | |||
| luminal A | 316 (62.6%) | 377 (63.1%) | 0.7843 |
| luminal B HER2 negative | 67 (13.3%) | 74 (12.4%) | 0.656 |
| luminal B HER2 positive | 46 (9.1%) | 47 (7.9%) | 0.4755 |
| non-luminal HER2 positive | 16 (3.2%) | 26 (4.4%) | 0.3023 |
| triple negative | 60 (11.9%) | 73 (12.2%) | 0.8789 |
| Simultaneous axillary lymph node dissection | 54 (10.7%) | 39 (6.5%) | 0.0124 |